



Bal Pharma Limited

To,
The Manager-Listing
BSE Limited
Mumbai.

19.09.2022

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of 35th Annual General Meeting ('AGM') held on 19.9.2022.
Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 35th Annual General Meeting of the Company conducted through audio visual means, on 19.09.2022.

Mr. Shailesh Siroya was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum.

Ordinary Business:

1. To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31,2022, the Statement of Profit and Loss for the financial year ended as on that date and the Cash Flow Statement together with the Reports of the Board of Directors and the Auditors thereon.
2. To declare dividend of Re.1/- per Equity Share of Rs. 10/- each.
3. To appoint a Director in place of Mr. Himesh Virupakshaya who is retiring by rotation and being eligible, offers himself for reappointment
4. To appoint SSJNB & Co, Chartered Accountants (Firm Registration No.: 013976S) as statutory auditors of the Company from the conclusion of 35th AGM to 40th AGM of the Company.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052, India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820



Special Business:

5. To adopt a new set of Memorandum of Association of the Company as per the provisions of Companies Act,2013.
6. To adopt a new set of Articles of Association of the Company as per the provisions of Companies Act,2013.
7. To revise the remuneration payable to Mr.Shailsh Siroya , Managing Director of the Company.
8. To revise the managerial remuneration payable to Mr. Himesh.V, Whole Time Director.
9. To appoint Mr. H.S Venkatesh as Director and also as independent Director of the Company for second term.
- 10.To appoint Mr. Kotian Chittanand Damodar as Director and also as a whole time Director of the Company and to fix his remuneration.
- 11.To ratify the remuneration payable to the Cost auditors for the financial year 2022.23.

Chairman briefed the shareholders about the performance of the Company during the financial year 2021.22 and later invited questions and/or clarifications from the members attending the meeting and the same were suitable addressed.

Mr.Prameshwar G Bhat, practising Company Secretary was appointed as the scrutinizer for the e-voting and the results of e-voting will be announced after receipt of Scrutinizer's Report.

The e-voting results will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also uploaded on our website.



Page-3

The 35th Annual General Meeting commenced at 11.00 AM as scheduled and concluded at 11.50 AM on 19.09.2022.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited.


Shailesh Siroya
Managing Director.

